A new screening procedure, an easy and specific assay for determining functional Protein S activity, has been developed, with use of Protein C activated by venom activator (Protac). Purified Protein C (100% amidolytic activity) was activated by venom activator (6 units/mL). To a mixture of 100 L of Protein S-deficient plasma, 20 L of sample plasma, 100 L of cephalin (Actin), and 20 L of activated Protein C we added 100 L of 25 mmol/L CaCI2 solution and measured the clotting time with a KC 10 coagulometer. The functional Protein S activity correlated well with the concentrations of Protein S antigen measured by enzyme immunoassay and the Laurell rocket technique (r = 0.810 and 0.850, respectively) in normal subjects, patients with myocardial infarction undergoing warfarin therapy, and patients with liver cirrhosis. Protein S functional activity by using Protein C activated by venom activator (Protac), without interference from the nonspecific activation of plasma.
MaterIals and Methods

Materials
Purified venom activator ("Protac," one vial contains 3 units of activity), goat IgG against human Protein S, and purified human Protein C were obtained from American Diagnostica, Greenwich, CT. One unit of Protac activates all the Protein C in 1 mL of normal plasma. Protein S-deficient human plasma was obtained from Diagnostica Stago, Asnieres, France. The concentration of Protein S antigen in Protein S-deficient plasma was less than 2% of the normal concentration in plasma as determined by enzyme-linked immunosorbent assay (EusA). Cephalin (Actin) and Owren's barbital buffer (50 mmolJL, pH 7.35) were purchased from American Dade, Miami, FL. Blood was collected into 38 g/L trisodium citrate solution, in a 9:1 ratio of blood to anticoagulant. Platelet-poor plasma (ppp) was prepared by centrifugation at 4#{176}C (2000 x g for 20 mm), then stored at -70 #{176}C until use. Normal plasma pooled from 26 ostensibly healthy normal subjects who had not been taking any drugs was used as standard plasma.
Because there is yet no generally purified reference standard for Protein 5, the activity in normal plasma is usually used in defining the unit of biological and immunological activity of ProteinS, i.e., the amount of activity in 1 mL of average normal plasma (usually a pooled specimen of 20 normal plasmas) (19) . The advantage of this system of units is that the severity of Protein S deficiency in a patient can be easily related to normal on a percentage scale. The Protein S activity in normal pooled plasma is stable for a month at -70 #{176}C, and the coefficient of variation (CV) for Protein S activity under these conditions is <5%. We also used citrated plasma samples from patients with myocardial infarction who were being treated with warfarin and from patients with liver cirrhosis.
Substances used for interference experiments were as follows. Biirubin (161 mgldL) was an aqueous standard solution (Nippon Shoji Co., Ltd., Tokyo, Japan), hemoglobin was a hemolysate of normal erythrocytes washed with isotonic saline solution and then lysed with distilled water, lipid was a fat emulsion used for intravenous administration (Intrafat; Takeda Co., Ltd., Tokyo, Japan). Vitamin C (L-ascorbic acid), heparin (heparin sodium salt, 198.3 units/ mg), and dipotassium ethylenediaminetetraacetic acid (EDTA) were from Wako Pure Chemical Industries Co., Ltd., Tokyo, Japan.
Methods
Activated Protein C was prepared by mixing 100 L of Protein C (diluted with Owren's barbital buffer, pH 7.35, to nonspecific activation of Protein S-deficient plasma by venom activator. In our assay system the final concentration of venom activator was <1 unit/mL. Therefore, there may have been no influence of nonspecific activation of Protein S-deficient plasma by venom activator in this assay system.
After mixing 10 pL of venom activator (6 units/mL) with 100 ,uL of Protein C (100% amidolytic activity), we studied the activation of Protein C kinetically at 37#{176}C (Figure 2) . The amidolytic activity of Protein C increased quickly, reaching a maximum after 15 miii, and after 45 mm it gradually decreased. Therefore, we measured Protein S activity from 15 to 45 miii after the activation of Protein C by venom activator.
To determine the effect of incubation time, afteradding activated Protein C, on clotting time, we assayed normal plasma, using incubation periods from 1 to 5 mm. Clotting time was longest after a 2-mm incubation. Therefore, we incubated the assay mixtures for 2 miii after adding activated Protein C.
The standard curve from 6.25% to 200% is shown in Figure 3 . Pooled normal plasma was diluted with Owren's barbital buffer or with Protein S-deficient plasma to obtain the various Protein S concentrations.Both standard curves are linear on a semilogarithm scale, but the slope is steeper for the standard curve incorporating data for standard diluted with Protein S-deficient plasma. Therefore, we usually used the latter standard curve but measured sample plasma without dilution.
We measured total Protein S antigen, using the standard curve for pooled normal plasma, and the value was the with 20 zL of venom activator (diluted with distilled water to 5 unita/mL), then incubating at 37#{176}C for 15 mm. We used an automated KC 10 coagulometer (Heinrich Amelung GmbH, Lieme, F.R.G.) to measure the clotting time.
To prepare the standard curve, we assayed standards having 0%, 6.25%, 12.5%, 25%, 50%, 100%, and 200% of the amount of Protein S in pooled normal plasma. The pooled normal plasma and the sample plasma were diluted with Owren's barbital buffer, pH 7.35, or Protein S-deficient plasma. When sample plasma was diluted twofold, pooled normal plasma without dilution thus contained twice the concentration of Protein S activity, comparatively speaking.
The assay was performed as follows. To the well of the KC 10 coagulometer add 20 pL of the standard or sample plasma, and 100 zL of Protein S-deficient plasma. After a 1-min incubation at 37#{176}C, add 100 p.L of cephalin. After 1 mm, add 10 zL of activated Protein C (69.7 g/mL).
Exactly 2 mm later, add 100 1zL of 25 mmol/L CaC12 solution and measure the clotting time.
We also assayed total Protein S antigen with an ELISA method (Asserachrom ProteinS; Diagnostica Stago, Francoville, France) and the Laurell rocket technique (11), using sample plasma. Protein S complexed to C4b-binding protein was precipitated Sampi.
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Between-run percentage of normal for total ProteinS antigen in pooled normal plasma. Free Protein S antigen was measured by using the standard curve for free Protein S of poolednormal plasma, and again the value was in terms of the percentage of free Protein S antigen in pooled normal plasma. Table 1 shows the precision, within-run and betweenrun.
Resultsof interference experiments are shown in Table  2 . A biirubin final concentration of 26 mg/dL, >0.1 unit of heparin per milliliter, and EDTA all interfered with the assay of Protein S functional activity. Figure 4 summarizes assay results for plasma samples from 31 normal subjects, 25 patients with liver cirrhosis, and 15 warfarun-treated patients with myocardial infarction. Free Protein S antigen as measured by the Laurell rocket technique or by ELISA exhibited good correlation with the Protein S functional activity (r = 0.850 and 0.810, respectively). Values for Protein S functional activity and antigen (total and free) and results for two casesof Protein S deficiency are shown in Table 3 .
DIscussIon
The naturally occurring anticoagulant proteins-Protein C, ProteinS, and antithrombin Ill-inhibit blood clotting, and several hereditary deficiencies and abnormalities among these proteins have been linked to predisposition to recurrent thrombosis (5, 8,21) in plasma is present both in the free form, which is the 3.79
active Protein C cofactor, and in a functionally inactive form that is complexed to complement compound C4b-binding protein (23) . These two forms of Protein S complicate diagnosis of Protein S deficiencies and abnormalities, because ordinary immunoassays do not distinguish between the free and bound forms (11). Most homozygous Protein S-deficient patients lack the free Protein S form but may have significant quantities of the bound inactive form (11). But most heterozygotes have concentrations of total Protein S antigen that are below the lower limit of the normal range (24) . Therefore, methods for assaying functional Protein S activity are needed, but existing ones are not yet feasible in most laboratories.
Our assay system of functional Protein S activity is simple and specific, because measurement of Protein C activity activated by venom activator (Protac) is easy, the standard curve is practicably steep, and in addition the functional activity is not influenced by the nonspecific activity of venom activator and shows good correlation with Protein S antigen as measured by ELISA and the Laurell rocket technique. Therefore, this assay method is useful in clinical laboratories for screening assay of functional Protein S activity.
In normal subjects, functional Protein S activity was 102% (SD 21%) and values for total and free Protein S antigen were 106% (SD 25%) and 106% (SD 20%), respectively. The ratio of Protein S functional activity to the 0.5 74 concentrations of total or free forms of Protein S assayed by ELISA in normal subjects is nearly 1.0. In our patients with myocardial infarction undergoing therapy with warfarin or in those with liver cirrhosis, the decreases in Protein S functional activity and antigen concentration (total and free forms) are prominent. And the ratio of functional activity to the free form of Protein S as assayed by ELISA decreased more prominently in patients undergoing therapy with warfarin than in patients with liver cirrhosis. But the ratio of the concentrations of free Protein S antigen to total Protein S antigen as assayed by ELISA is also nearly 1.0. Therefore, in patients being treated with warfarin there would be decreased synthesis of the total and free forms of Protein S antigen accompanying the production of incompletely y-carboxylatedand dysfunctional free form of Protein S. These discrepancies between Protein S functional activity and Protein S antigen were also recognized in other reports (15, 17) .
During a screening examination of healthy subjects, we found two cases of Protein S deficiency. Both cases were type ll, as based on a report by Comp et al. (11) , and the patients themselves had no thrombotic episodes nor did their families.
Evaluation of Protein S functional activity by a simple and specific screening assay method, both in healthy subjects and patients with thrombosis, is quite useful and is urgently needed to treat such patients and to analyze the mechanism and pathophysiology of thrombosis.
